Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities

Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities

Jie Pan,1 Qiuyan Li,1 Yan Sun,1 Yingying Gu,1 Yijie Ding,1 Nengzhi Pang,1 Yujia Zhou,1 Lei Pei,1 Mengqi Gao,1 Sixi Ma,1 Ying Xiao,1 Feilong Wu,1 De Hu,1 Yu-Ming Chen,2 Lili Yang1 1Department of Nutrition, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun...

Full description

Bibliographic Details
Main Authors:	Pan J, Li Q, Sun Y, Gu Y, Ding Y, Pang N, Zhou Y, Pei L, Gao M, Ma S, Xiao Y, Wu F, Hu D, Chen YM, Yang L
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-01-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	metabolic dysfunction-associated fatty liver disease adipsin metabolic risk abnormalities hepatic steatosis
Online Access:	https://www.dovepress.com/increased-serum-adipsin-correlates-with-mafld-and-metabolic-risk-abnor-peer-reviewed-fulltext-article-DMSO

Similar Items

Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria
by: Jie Pan, et al.
Published: (2023-03-01)

Comparison of MAFLD and NAFLD Characteristics in Children
by: Yunfei Xing, et al.
Published: (2023-03-01)

Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis
by: Tymofiy Lutsiv, et al.
Published: (2023-01-01)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China
by: Xite Lin, et al.
Published: (2023-03-01)

Adipsin Serum Concentrations and Adipose Tissue Expression in People with Obesity and Type 2 Diabetes
by: Margarete Milek, et al.
Published: (2022-02-01)

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study
by: Wang QX, et al.
Published: (2022-08-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease
by: Chang-Hai Liu, et al.
Published: (2022-06-01)

Correlation between serum uric acid and body fat distribution in patients with MAFLD
by: Min Tao, et al.
Published: (2023-09-01)

<b>Analytical methods for evaluation of the fatty acid metabolism in rat liver
by: Eduardo Hideo Gilglioni, et al.
Published: (2018-11-01)

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
by: Kamlesh K. Bhopale, et al.
Published: (2023-10-01)

MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
by: Huang J, et al.
Published: (2021-07-01)

MAFLD in Obese Children: A Challenging Definition
by: Anna Di Sessa, et al.
Published: (2021-03-01)

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
by: Tafere GG, et al.
Published: (2020-05-01)

Adipsin – summing up large-scale results: A review
by: Vladimir V. Salukhov, et al.
Published: (2022-07-01)

Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells
by: Nicole Aaron, et al.
Published: (2021-06-01)

Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
by: Cao W, et al.
Published: (2021-09-01)

A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
by: Qiling Liu, et al.
Published: (2022-11-01)

The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction
by: Su-bin Lee, et al.
Published: (2024-03-01)

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
by: Chen X, et al.
Published: (2022-03-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease
by: Abdulrahman Ismaiel, et al.
Published: (2021-11-01)

Development and validation of a new nomogram to screen for MAFLD
by: Haoxuan Zou, et al.
Published: (2022-12-01)

Adipsin alleviates cardiac microvascular injury in diabetic cardiomyopathy through Csk-dependent signaling mechanism
by: Xuebin Zhang, et al.
Published: (2023-05-01)

Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy
by: Layla Othman Farhan, et al.
Published: (2023-06-01)

Hepatic steatosis in women with polycystic ovary syndrome
by: Xinyu Hong, et al.
Published: (2023-09-01)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
by: Nan Yao, et al.
Published: (2022-06-01)

Biochemical assessment of metabolic associated fatty liver disease
by: Guerra-Ruiz Armando R., et al.
Published: (2021-03-01)

Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis
by: Adrian Kołakowski, et al.
Published: (2022-09-01)

Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population
by: Arno R. Bourgonje, et al.
Published: (2022-12-01)

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2022-08-01)

Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD
by: Pia Fahlbusch, et al.
Published: (2022-06-01)

Exercise Promotes Bone Marrow Microenvironment by Inhibiting Adipsin in Diet-Induced Male Obese Mice
by: Zunhan Shi, et al.
Published: (2022-12-01)

Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study
by: Shuhei Fukunaga, et al.
Published: (2021-05-01)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
by: Pallavi Subramanian, et al.
Published: (2022-06-01)

Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population
by: Jieun Chung, et al.
Published: (2021-11-01)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
by: Qin Guo, et al.
Published: (2023-08-01)

Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD) and Thyroid Function in Childhood Obesity: A Vicious Circle?
by: Valeria Calcaterra, et al.
Published: (2024-02-01)

The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease
by: Ji-Yeon Seo, et al.
Published: (2021-10-01)

Editorial: Interaction of endocrine disorders and metabolic associated fatty liver disease: the genetic and epigenetic basis
by: Qin Pan, et al.
Published: (2023-11-01)